Sign in
Taking people in United StatesEarly phase 1

PET Scan Tracer Study for Alpha Synuclein Clumps in the Brain

Tests a brain scan tracer that detects alpha synuclein clumps in Parkinson's and related diseases.

Key facts

Who runs it
Massachusetts General Hospital
Where
Charlestown, United StatesSee the site
Trial code
Registry title
PET Imaging Evaluation of [11C]SY08
Status
Recruiting
Phase
Early phase 1
People taking part
40 people, planned
Started
1 May 2024
Expected to end
Nov 2027
Type of study
Interventional
Treatments tested
  • C11-SY08
Record updated
24 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 to 80 with Parkinson's disease, multiple system atrophy or dementia with Lewy bodies, and healthy volunteers. All have one PET/MRI brain scan with the tracer [11C]SY08.

Age
50 to 80 years
Sex
All sexes can join.
Disease stage
Parkinson's disease: Hoehn and Yahr stage I-IV. Multiple system atrophy: MSAp or MSAc type. Dementia with Lewy bodies: probable DLB with Clinical Dementia Rating Scale (CDR) < 0.5. Healthy volunteers can also join.
Earlier treatment
Patients must have been on stable medications for at least 30 days.

Main reasons for not taking part

  • Stroke, head injury or focal brain lesions on MRI
  • Major psychiatric disease or current substance abuse
  • Pregnancy or breastfeeding
  • Metal implants, pacemakers or fear of enclosed spaces that prevent an MRI scan
  • Recent radiation exposure that would go above the allowed limit of 50 milliSieverts

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • General Inclusion criteria, all subjects must:; Age 50-80; Be able to provide written informed consent or assent; Be able to read, speak and understand English (The investigators do not have the resources necessary to properly study non-English speaking patients in this study, given that translation and validation of the assessment tools would be necessary); Be willing and able to participate in one PET/MRI scanning session; Additional Inclusion criteria for PD patients, subjects must:
  • Have an existing diagnosis of idiopathic PD, using consensus criteria
  • Stable medications for at least 30 days
  • Hoehn and Yahr stage I-IV
  • A study partner who can answer questions pertaining to daily functioning; Additional Inclusion criteria for MSA patients, subjects must:
  • Have an existing diagnosis of MSA, using consensus criteria
  • Stable medications for at least 30 days
  • MSAp or MSAc
  • A study partner who can answer questions pertaining to daily functioning; Additional Inclusion criteria for DLB patients, subjects must:
  • Have an existing diagnosis of probable DLB, using consensus criteria
  • Stable medications for at least 30 days
  • Clinical Dementia Rating Scale (CDR) < 0.5
  • A study partner who can answer questions pertaining to daily functioning

Who cannot take part

  • Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, steel implants, ferromagnetic objects such as jewelry or metal clips in clothing
  • General Exclusion Criteria (All Subjects); History of vascular risk factors (e.g. hypertension, hyperlipidemia), if not well-controlled; Major psychiatric disease (e.g.schizophrenia); History of stroke; Focal brain lesions on MRI scans; History of other major illnesses including, but not limited to, major kidney or liver problems or significant neurological illness; Recent surgery that is deemed major by our reviewing physician or nurse practitioner within the past 6 months; History of head trauma (as defined as having any insults to the brain that may have resulted from an external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile); Impaired elimination (as defined as having problems with urination) unless being managed; Past or present diagnosis of bipolar disorder or other Axis I diagnosis, (treated depression is allowed); Any present substance abuse including drug/alcohol abuse; Inability to lie flat on camera bed for up to 90 min; Pregnancy or breastfeeding; Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan; Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits (50 milliSieverts); General MR and PET safety exclusion criteria listed below
  • Electrical implants such as cardiac pacemakers or perfusion pumps
  • Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
  • Raynaud syndrome
  • Bleeding disorder
  • An allergy to Lidocaine
  • Pregnancy: A negative serum pregnancy test is required on the day of the PET procedure in women of child bearing potential
  • Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for 60 to 90 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis)
  • Body weight of > 300 lbs (weight limit of the MRI table)
  • Breast feeding mothers
  • An abnormal result on the modified Allen's test on both hands
  • Use of anticoagulants such as Coumadin, Plavix or Lovenox

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 80 years old?

Where in United States

  • MGHCharlestown, United StatesContact: Changning WangTaking people

About the trial

What the trial wants to find out

The overall goal of the proposed research is to evaluate the use of [11C]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls.

Read full original descriptionShow less

The purpose of this study is to evaluate the use of [11C]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are:

1. To determine brain uptake, distribution, and kinetics of [11C]SY08 in healthy individuals. 2. To determine brain uptake, distribution, and kinetics of [11C]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA. 3. To determine human dosimetry of [11C]SY08 in healthy individuals

An intravenous bolus injection of [11C]SY08 will be administered per subject for brain PET imaging.

The group in the trial

  • evaluation of alpha synuclein aggregates in the brainTreatment being tested

    Treatment: C11-SY08

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PET Imaging Evaluation of [11C]SY08
Plain-language title
PET Scan Tracer Study for Alpha Synuclein Clumps in the BrainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06098612, who can take part
Record updated
24 December 2025